logo
Share SHARE
FONT-SIZE Plus   Neg

BioLineRx Announces Extension Of Patent For BCM By USPTO - Quick Facts

BioLineRx (BLRX) said an Issue Notification has been received from the United States Patent and Trademark Office granting 1,787 days of Patent Term Adjustment for the patent claiming the composition of BCM (BL-1040), a novel medical device for prevention of cardiac remodeling following an acute myocardial infarction.

Accordingly, the term of this patent will now extend through at least the end of April 2029, which is almost three years longer than previously reported by the company. Additional patents claiming the BL-1040 composition and its use for the treatment of ventricular remodeling and congestive heart failure due to acute myocardial infarction are granted or pending in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and Australia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Telecommunications firm Sprint has extended its Black Friday unlimited data offer for a limited time, the company said in a statement on Monday. When customers switch at least one line to Sprint and sign up for Unlimited Freedom with AutoPay, they get unlimited data, talk and text starting at just $20 per month/line for a family of five until January 31, 2018. Shares of Cerecor Inc. (CERC) plunged over 13% on Monday on disappointing top-line clinical results from its phase II clinical trial of CERC-501 for smoking cessation. A US accounting watchdog slapped $8 million fine on Deloitte's Brazil division for issuing false audits of US-traded Brazilian airline Gol Intelligent Airlines in 2010. The agency also said that the company then doctored papers to thwart an investigation. The Public Company Accounting Oversight Board or PCAOB also announced a $750 thousand settlement with Deloitte Mexico.
comments powered by Disqus
Follow RTT